Compare ABCL & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABCL | IRTC |
|---|---|---|
| Founded | 2012 | 2006 |
| Country | Canada | United States |
| Employees | N/A | 2400 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.7B |
| IPO Year | 2020 | 2016 |
| Metric | ABCL | IRTC |
|---|---|---|
| Price | $12.61 | $110.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | $8.40 | ★ $197.92 |
| AVG Volume (30 Days) | ★ 4.4M | 450.2K |
| Earning Date | 05-11-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 10.91 | ★ 61.71 |
| EPS | ★ N/A | N/A |
| Revenue | $75,128,000.00 | ★ $747,138,000.00 |
| Revenue This Year | N/A | $19.60 |
| Revenue Next Year | $21.85 | $15.94 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 160.56 | 26.24 |
| 52 Week Low | $2.75 | $100.85 |
| 52 Week High | $13.18 | $210.01 |
| Indicator | ABCL | IRTC |
|---|---|---|
| Relative Strength Index (RSI) | 65.97 | 38.47 |
| Support Level | $10.38 | $102.62 |
| Resistance Level | N/A | $127.33 |
| Average True Range (ATR) | 0.61 | 4.57 |
| MACD | -0.01 | -1.14 |
| Stochastic Oscillator | 79.02 | 14.04 |
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.